Results for tag: "Volibris"

The Volibris market is a segment of the cardiovascular drug industry that focuses on the development and commercialization of drugs for the treatment of pulmonary arterial hypertension (PAH). These drugs are designed to improve the quality of life of patients with PAH by reducing symptoms such as shortness of breath, fatigue, and chest pain. The Volibris market is composed of a variety of pharmaceutical companies, including those that specialize in the development of new drugs and those that focus on the marketing and distribution of existing drugs. The Volibris market is highly competitive, with companies competing to develop and market the most effective drugs. Companies in the market are also competing to develop new formulations of existing drugs, as well as to develop new drugs that target different aspects of PAH. Companies in the Volibris market include Actelion Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics. Show Less Read more